p53 binds to cisplatin-damaged DNA
- PMID: 11342217
- DOI: 10.1016/s0167-4781(00)00305-5
p53 binds to cisplatin-damaged DNA
Abstract
We have previously shown that bacterially expressed p53 protein or p53 protein isolated from cis-diamminedichloroplatinum II (cisplatin)-damaged cells is capable of binding to double-stranded platinated DNA molecules lacking any p53 DNA binding sites. Here we report using various p53 mutants that two separate domains of p53 protein affect p53 binding to platinated DNA. Mutations within the central core of p53, the domain responsible for sequence-specific DNA binding activity, completely eliminated p53 binding to platinated DNA. Based on competition experiments p53 preferred binding to sequence-specific DNA molecules over platinated DNA molecules. However, p53 binding to platinated DNA molecules was significantly stronger than p53 interactions with DNA molecules lacking damage and a p53 consensus site. Finally, an antibody specific to the C-terminal domain of p53 (pAb421) which activates sequence-specific DNA binding activity inhibited p53 binding to platinated DNA. Taken together, these results suggest that in addition to binding to p53 DNA binding sites, p53 also interacts with cisplatin-damaged DNA molecules.
Similar articles
-
Recognition of DNA modified by antitumor cisplatin by "latent" and "active" protein p53.Biochem Pharmacol. 2003 Apr 15;65(8):1305-16. doi: 10.1016/s0006-2952(03)00078-9. Biochem Pharmacol. 2003. PMID: 12694871
-
DNA binding activities of p53 protein following cisplatin damage of ovarian cells.Oncol Res. 1998;10(3):151-61. Oncol Res. 1998. PMID: 9700726
-
Recognition of cisplatin-damaged DNA by p53 protein: critical role of the p53 C-terminal domain.Biochem Biophys Res Commun. 2006 Jan 13;339(2):477-84. doi: 10.1016/j.bbrc.2005.11.038. Epub 2005 Nov 15. Biochem Biophys Res Commun. 2006. PMID: 16300733
-
p53 protein at the hub of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding.Carcinogenesis. 2001 Jun;22(6):851-60. doi: 10.1093/carcin/22.6.851. Carcinogenesis. 2001. PMID: 11375889 Review.
-
Interaction of tumor suppressor p53 with DNA and proteins.Curr Pharm Biotechnol. 2010 Jan;11(1):122-7. doi: 10.2174/138920110790725366. Curr Pharm Biotechnol. 2010. PMID: 20214611 Review.
Cited by
-
Versatile functions of p53 protein in multicellular organisms.Biochemistry (Mosc). 2007 Dec;72(13):1399-421. doi: 10.1134/s0006297907130019. Biochemistry (Mosc). 2007. PMID: 18282133 Free PMC article. Review.
-
Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING-dependent therapy-induced senescence and provides "one-two punch" opportunity with anti-PD-L1 therapy in colorectal cancer.Cancer Sci. 2023 Nov;114(11):4184-4201. doi: 10.1111/cas.15961. Epub 2023 Sep 13. Cancer Sci. 2023. PMID: 37702298 Free PMC article.
-
Regulation of P53 signaling in breast cancer by the E3 ubiquitin ligase RNF187.Cell Death Dis. 2022 Feb 14;13(2):149. doi: 10.1038/s41419-022-04604-3. Cell Death Dis. 2022. PMID: 35165289 Free PMC article.
-
Cellular responses to Cisplatin-induced DNA damage.J Nucleic Acids. 2010 Aug 8;2010:201367. doi: 10.4061/2010/201367. J Nucleic Acids. 2010. PMID: 20811617 Free PMC article.
-
PD-1/PD-L1 and DNA Damage Response in Cancer.Cells. 2023 Feb 7;12(4):530. doi: 10.3390/cells12040530. Cells. 2023. PMID: 36831197 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous